A Phase IIb Randomised, Double Blind, Placebo Controlled Parallel Group Study To Investigate The Efficacy And Safety Of PF-00610355 Over 4 Weeks In Moderately Asthmatic Subjects.

Trial Profile

A Phase IIb Randomised, Double Blind, Placebo Controlled Parallel Group Study To Investigate The Efficacy And Safety Of PF-00610355 Over 4 Weeks In Moderately Asthmatic Subjects.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs PF 610355 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2011 Planned patient number is 356 according to European Clinical Trials Database.
    • 14 Mar 2011 Last checked against ClinicalTrials.gov record.
    • 14 Mar 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top